Comparison of Methanolic Extract of Piper Betle to Amikacin against the Growth of Pseudomonas aeruginosa

Authors

  • Azalia Ayu Rysaputri Medical Study Program Faculty of Medicine Universitas Brawijaya Malang
  • Hery Susilo Department of Oncological Surgery Faculty of Medicine Universitas Brawijaya Malang
  • Dwi Yuni Nur Hidayati Department of Microbiology Faculty of Medicine Universitas Brawijaya Malang
  • Irene Ratridewi Department of Pediatric Faculty of Medicine Universitas Brawijaya Malang

DOI:

https://doi.org/10.21776/ub.jkb.2023.032.03.3

Keywords:

Amikacin, antibacterial, Piper betle L., Pseudomonas aeruginosa

Abstract

Pseudomonas aeruginosa is one of the most common pathogens that cause Healthcare-Associated Infections (HAIs). A previous study stated that Piper betle L. extract has antibacterial activity against certain bacteria, including Pseudomonas aeruginosa. This study has the objective of comparing antibacterial activity of the methanolic extract of Piper betle L. and amikacin on the growth of Pseudomonas aeruginosa. This study used the tube dilution method with a sample of Pseudomonas aeruginosa from Microbiology Laboratory Dr. Saiful Anwar General Hospital, Malang. The results of this study showed that the value of MIC and MBC from the methanolic extract of the Piper betle L. treatment was 4800μg/mL. Meanwhile, the amikacin treatment resulted in 0.4μg/mL for MIC and 0.45μg/mL for MBC. From linear regression, it was found that the methanolic extract of Piper betle L. had a β-coefficient value closer to -1 compared to amikacin. Therefore, it can be concluded that the methanolic extract of Piper betle L. has a greater inhibiting effect on the growth of Pseudomonas aeruginosa.

Downloads

Download data is not yet available.

References

Haque M, Sartelli M, McKimm J, and Bakar MA. Health Care-associated Infections – An Overview. Infection and Drug Resistance. 2018; 11: 2321–2333.

Sharma G, Rao S, Bansal A, Dang S, Gupta S, and Gabrani R. Pseudomonas Aeruginosa Biofilm: Potential Therapeutic Targets. Biologicals. 2014; 42(1): 1-7.

Alhazmi A. Pseudomonas aeruginosa – Pathogens and Pathogenic Mechanisms. International Journal of Biology. 2015; 7(2): 44-67.

Pacifici GM and Marchini G. Clinical Pharmacokinetics of Amikacin in Neonates. International Journal of Pediatrics. 2017; 5(2): 4407- 4428.

Smits A, Kulo A, Anker JVD, and Allegaert K. The Amikacin Research Program: A Stepwise Approach to Validate Dosing Regimens in Neonates. Expert Opinion on Drug Metabolism & Toxicology. 2017; 13(2): 157-166.

Dasgupta A. Advances in Antibiotic Measurement. Advances in Clinical Chemistry. 2012; 56: 75-104.

Syahidah A, Saad CR, Hassan MD, Rukayadi Y, Norazia MH, and Kamarudin MS. Phytochemicals Analysis, Identification and Quantification of Antibacterial Active Compounds in Betel Leaves, Piper betle Methanolic Extract. Pakistan Journal of Biological Sciences. 2017; 20(2): 70-81.

Madduluri S, Rao KB, and Sitaram B. In Vitro Evaluation of Antibacterial Activity of Five Indigenous Plants Extract Against Five Bacterial Pathogens of Human. International Journal of Pharmacy and Pharmaceutical Sciences. 2013; 5(4): 679-684.

Shields P and Cathcart L. Oxidase Test Protocol. American Society for Microbiology. (Online) 2010. https://asm.org/getattachment/00ce8639-8e76-4acb-8591-0f7b22a347c6/oxidase-test-protocol-3229.pdf

Hall S, McDermott C, Anoopkumar-Dukie S, McFarland AJ, et al. 2016. Cellular Effects of Pyocyanin, a Secreted Virulance Factor of Pseudomonas aeruginosa. Toxins. 2016; 8(8): 1-14.

Jamelarin EM and Balinado LO. Evaluation of Antibacterial Activity of Crude Aqueous, Ethanolic and Methanolic Leaf Extracts of Piper retrofractum Vahl. and Piper betle L. Asian Journal of Biological and Life Sciences. 2019; 8(2): 63-67.

Ramirez MS and Tolmasky ME. Amikacin: Uses, Resistance, and Prospects for Inhibition. Molecules. 2017; 22(12): 1-23.

Sutherland CA, Verastegui JE, and Nicolau DP. In Vitro Potency of Amikacin and Comparators Against E. coli, K. pneumoniae and P. aeruginosa Respiratory and Blood Isolates. Annals of Clinical Microbiology and Antimicrobials. 2016; 15(1): 1-7.

Downloads

Published

2023-02-27 — Updated on 2023-05-08

Versions

Issue

Vol. 32 No. 3 (2023)

Section

Research Article

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).